#REGN Schleifer (cont'd): " So, I think that we don't get to set the policy. We hopefully get to influence a little bit, and we try and work through it." 8/

#REGN Schleifer (cont'd): "Obviously, experience does matter, and I really hope that we do not lose really good people at the FDA in the rank and file or even at the policy level. I think that would be deleterious." 7/

#REGN Schleifer (cont'd): "And I think that there are others who feel similarly as I do, that we can't lose the ability to do science. If we take a path where we just stop following science and we give up on tried and true methodologies, I think we could be in trouble." 6/

Risinger asked a similar question of #REGN c-suite team, and Len Schleifer at least gave a somewhat honest reply: "I told the President that I thought that RFK Jr, while he thinks outside the box, needed some assistance on the science front. I said that straight out and offered to provide that." 5/

I've been frankly flummoxed at how supine #pharma and #biotech has been through the first three months of this presidency, and CEO Rob Michael's "glittering generalities" response didn't suggest to me it would become more robust. 4/4

"... can you please comment on how your executive team and board are engaging differently today with Washington leadership to change the political agenda for the better?" 3/4

"... and also the Trump administration's agenda to take prices down more than the Biden administration took down drug prices. So considering what appears to be a lack of appreciation in Washington of the benefits that the biopharmaceutical industry brings to Americans ..." 2/4

The number of things he's said that are flat wrong, misleading, and uninformed is shocking. I've sat through a lot of confirmation hearings and I've never seen a performance like this. He is simply flat wrong on the amyloid hypothesis. There are two drugs now approved that block amyloid.

RFK: "Almost nothing is studied at NIH about the etiology of our chronic disease epidemic."

NIH:

Moreover, $BIOA is the first time in awhile I can recall that liver enzyme elevations derailed a drug other than a gene therapy. It feels like companies are getting more sophisticated in getting that AE risk out of the way before they go into human testing. #biotech #pharma

We know obesity is, counterintuitively, a disease of poverty in the USA. I need to hear drug developers talk about this more. Getting Medicaid to cover Wegovy, Zepbound and their followers won't be an answer.